Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Ig-free light chains play a crucial role in murine mast cell-dependent colitis and are associated with human inflammatory bowel diseases.

Rijnierse A, Redegeld FA, Blokhuis BR, Van der Heijden MW, Te Velde AA, Pronk I, Hommes DW, Nijkamp FP, Koster AS, Kraneveld AD.

J Immunol. 2010 Jul 1;185(1):653-9. doi: 10.4049/jimmunol.0901129. Epub 2010 May 26.

2.

Critical role for mast cells in the pathogenesis of 2,4-dinitrobenzene-induced murine colonic hypersensitivity reaction.

Rijnierse A, Koster AS, Nijkamp FP, Kraneveld AD.

J Immunol. 2006 Apr 1;176(7):4375-84.

3.

TNF-alpha is crucial for the development of mast cell-dependent colitis in mice.

Rijnierse A, Koster AS, Nijkamp FP, Kraneveld AD.

Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G969-76. Epub 2006 Jun 22.

4.

Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?

Te Velde AA, Pronk I, de Kort F, Stokkers PC.

Eur J Gastroenterol Hepatol. 2008 Jun;20(6):555-60. doi: 10.1097/MEG.0b013e3282f45751.

PMID:
18467915
6.

Beneficial effect of tachykinin NK1 receptor antagonism in the development of hapten-induced colitis in mice.

Rijnierse A, van Zijl KM, Koster AS, Nijkamp FP, Kraneveld AD.

Eur J Pharmacol. 2006 Oct 24;548(1-3):150-7. Epub 2006 Jul 25.

PMID:
16949572
7.

Key role for mast cells in nonatopic asthma.

Kraneveld AD, van der Kleij HP, Kool M, van Houwelingen AH, Weitenberg AC, Redegeld FA, Nijkamp FP.

J Immunol. 2002 Aug 15;169(4):2044-53.

8.

Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease.

Farhadi A, Keshavarzian A, Fields JZ, Jakate S, Shaikh M, Banan A.

J Gastroenterol Hepatol. 2007 Dec;22(12):2338-43. Epub 2007 Jul 20.

PMID:
17645464
9.

Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses.

Redegeld FA, van der Heijden MW, Kool M, Heijdra BM, Garssen J, Kraneveld AD, Van Loveren H, Roholl P, Saito T, Verbeek JS, Claassens J, Koster AS, Nijkamp FP.

Nat Med. 2002 Jul;8(7):694-701. Epub 2002 Jun 17.

PMID:
12068287
10.

Functional abnormalities in the intestine associated with mucosal mast cell activation.

Crowe SE, Perdue MH.

Reg Immunol. 1992 Mar-Apr;4(2):113-7.

PMID:
1503888
11.

A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S.

J Clin Invest. 2004 Nov;114(10):1444-56. Retraction in: Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. J Clin Invest. 2006 Jul;116(7):2056.

12.

DNFB-DNS hapten-induced colitis in mice should not be considered a model of inflammatory bowel disease.

Bailón E, Cueto-Sola M, Utrilla P, Nieto A, Garrido-Mesa N, Celada A, Zarzuelo A, Xaus J, Gálvez J, Comalada M.

Inflamm Bowel Dis. 2011 Oct;17(10):2087-101. doi: 10.1002/ibd.21586. Epub 2010 Dec 22.

PMID:
21910170
13.

Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease.

Andoh A, Deguchi Y, Inatomi O, Yagi Y, Bamba S, Tsujikawa T, Fujiyama Y.

Oncol Rep. 2006 Jul;16(1):103-7.

PMID:
16786130
14.

Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.

Gironella M, Iovanna JL, Sans M, Gil F, Peñalva M, Closa D, Miquel R, Piqué JM, Panés J.

Gut. 2005 Sep;54(9):1244-53. Epub 2005 May 3.

15.

Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.

Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H.

Gut. 2009 Jun;58(6):790-8. doi: 10.1136/gut.2008.153981. Epub 2008 Oct 31.

PMID:
18978179
16.

Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.

Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M.

Eur J Immunol. 1996 Apr;26(4):934-8.

PMID:
8625991
17.

Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease.

Nishida Y, Murase K, Isomoto H, Furusu H, Mizuta Y, Riddell RH, Kohno S.

Hepatogastroenterology. 2002 May-Jun;49(45):678-82.

PMID:
12063968
18.

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.

Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R.

J Pathol. 2008 Oct;216(2):183-92. doi: 10.1002/path.2394.

PMID:
18729068
19.

Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease.

Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, Maschek H, Stolte M, Gebel M, Manns MP.

Histopathology. 1996 Jan;28(1):1-13.

PMID:
8838115
20.

Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease.

Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B, Kovari E, Herrmann F, Hadengue A, Krause KH.

J Pathol. 2005 Oct;207(2):164-76.

PMID:
16086438

Supplemental Content

Support Center